17.06.2026

Ongoing research domains - Oncology

In early 2026, we released our 2025 Science and Innovation Report. This edition highlighted, amongst other things, advances in the field of oncology, which we have set out below.

Dr. Matti Aapro (Clinique de Genolier)

Matti Aapro has continued to make significant contributions to oncology, focusing on geriatric cancer care, supportive treatments, and access to treatment. Corticosteroid therapy in older adults with cancer has thus been reviewed recently in work from Expert SIOG (International Society of Geriatric Oncology) (J Geriatr Oncol). He co-authored a ground-breaking work demonstrating prospectively how to improve antiemetic control by factoring in patient characteristics (MyRisk trial Annals of Oncology). The recent changes in European Health Technology Assessment rules prompted a group in which he has worked for several years (RWE4Decisions) to publish some comments on the use of real world evidence (Int J Technol Assess Health Care).

In pursuit of his involvement with bone health in cancer patients he participated in a joint position paper of many Societies on the management of aromatase inhibitor-associated bone loss (AIBL) in women with hormone-sensitive breast cancer (J Bone Oncol) and was first author of a review of denosumab (Expert Opin Biol Ther) A crucial topic with the rapid development of new agents for cancer therapy is the integration of better guidance for side-effect management early in phase I development, a work reported in ESMO open.

Guidelines tend to concentrate on the work in rich countries and with patients treated in centers of excellence. Yet the majority of patients is elsewhere.

Thus, Matti Aapro and colleagues have evaluated geriatric assessment recommendations on a global perspective, in an ASCO supported collaborative effort (JCO Glob Oncol) and discussed MASCC antiemetic consensus recommendations in resource-limited settings (Support Care Cancer) and underserved patient populations with metastatic breast cancer (Breast J).

Further recent work on antiemetics also comprises of a joint paper on nausea and vomiting related to ntibody-drug conjugates (Future Oncol). Trilaciclib is a CDK4 / 6 inhibitor which showed some promising activity to decrease drug-related neuropenia, an area of long-standing interest for Aapro (JNCI Cancer Spectr). In educational efforts, Aapro co-directed a course on «Improving cancer outcomes through enhanced leadership and strategy training for cancer healthcare professionals – with European School of Oncology (ESO), the European Cancer Organization (ECO) and Sharing Progress in Cancer Care (SPCC). (J Cancer Policy. 2025)».

About Matti Aapro

Furthermore, he is President of SPCC and directed its educational efforts (see SPCC.net and Oncocorner.net). He is head of the Oncodaily medical journal.Matti Aapro was appointed in 2025 as permanent Board member of All.

Can international, launched by him and colleagues in December 2016 as multi-stakeholder initiative, acquired legal status as a non-profit organization (ASBL) in Belgium in May 2020 and whose purpose is to improve patients’ pathways using existing resources more efficiently.

He remains Board member of the Union for International Cancer Control (UICC) and participates in the European Cancer Organization (ECO) International Committee.

Scientific outputs (research, reviews, policy)

In 2025, Alexandru Eniu’s publications formed a coherent arc from system-level access and leadership to clinic-level affordability and genetics: (1) a global call-to-action in Breast on equitable access to comprehensive ABC care (2025–2035); (2) an ASCO Educational Book chapter on financial toxicity – who is at risk and how to intervene; (3) a Journal of Cancer Policy article detailing the ESO / ECO / SPCC leadership and strategy course; and (4) a Diseases retrospective study clarifying the relationship between BRCA status and reproductive outcomes in Romania (see full articles references in the Science and Innovation rapport «Publications» section).

Clinical Research

Eniu served as Principal Investigator for the successful activation of the TROPION phase III breast cancer clinical trial at the Genolier Campus. He led site coordination with the sponsor and CRO, oversaw regulatory and contractual processes, and worked closely with pharmacy, research, and clinical teams, resulting in timely site initiation and readi ness for patient enrollment.

Invited talks, faculty roles & moderation

Lac Leman Regenerative Medicine Symposium

– March 5–7 – SSS Diploma, Module 1A – Lausanne, Switzerland – Hotel Aquatis – Faculty, Medical Oncology («Follow-up of Breast Cancer» and «Treatment of DCIS»).

ASCO Annual Meeting (panel)

May 30, Chicago, USA – Invited Faculty, Chair and Speaker («Financial Toxicity of Breast Cancer Care: What It Is, Who Is Impacted, and Should I Care About It?»).

ABC8

Lisbon (Nov 6–8, 2025): Consensus Panelist and Invited Faculty / Speaker («Learnings from the Global Decade Report 2015-2025 (*Goal 9)») November 15, 2025: Public conference (Clinique de Montchoisi & GIST Romande Group): «Breast Cancer: An Overview.», Lausanne.

European Cancer Summit 2025

Brussels (Nov 19–20, 2025): co chair / moderator for the Digital Health Network session («Artificial Intelligence and Cancer Care: A Paradigm Shift in Progress»).

European School Of Oncology (ESO) courses (Chairman and Faculty):

Contributed to several events: Improving Cancer Outcomes & Leadership, Masterclass in Clinical Oncology

Summer Edition, Basic Principles in Oncology

ESO College Convention, ESO Breast Refresher as part of programme mapping and delivery.

Dr. Alex Friedlaender (Clinique Générale-Beaulieu, Geneva)

In 2025, Alex Friedlaender co-authored three high-impact, peer-reviewed publications that reinforced Swiss Medical Network’s scientific contribution to thoracic oncology and precision immuno-oncology, with a strong focus on real-world outcomes research and molecularly targeted strategies in lung cancer. Two flagship papers from the Pembro-real 5-year global registry investigated advanced NSCLC with PD-L1 ≥ 50 % treated with first-line pembrolizumab outside clinical trials.

One study identified key determinants of 5-year survival, providing clinically actionable insight into long-term prognosis in real-world practice. A companion publication lever aged a transformer-based AI model to capture time-dependent prognostic complexity, illustrating how advanced analytics can refine risk stratification and outcome prediction in immunotherapy-treated populations.

Complementing these registry analyses, a comprehensive review on BRAF targeting across solid tumors summarized molecular mechanisms and clinical applications, supporting therapy selection and development of targeted approaches across oncology indications.

Dr. Michael Montemurro (Clinique de Genolier)

Guidelines

Gastrointestinal Oncology Standards – 3rd edition of the guidelines of the Zurich Digestive Tumors Network. M. Montemurro contributed to the drafting of these guidelines, which have now been published in their 3rd edition.

Volunteering

Montemurro took part in two charity half-marathons, for which reason he was nominated for the 2025 Excellence Awards of University College London Hospital.

Talks / Congress

European Colorectal Congress 2025 – Invited Speaker
1. Update on Gastrointestinal Stromal Tumors
2. Immunotherapy for metastatic and non-metastatic disease
Conferences

On April 25, Michael Montemurro hosted and chaired the 22nd Annual Meeting of the Swiss GIST (www.gist.ch – GIST GastroIntestinaleStromaleTumeur). This oncology focused day, held at the Genolier Innovation Hub, was open to the general public, patients, healthcare professionals, and researchers. It highlighted recent scientific and technological advances in cancer care, expanding beyond gastrointestinal stromal tumors (GIST) to address current and emerging topics in oncology. The program brought together leading experts from oncology, artificial intelligence and digital health, academic research, patient advocacy, and the cultural sector. Discussions addressed both scientific progress and the broader human and societal challenges associated with cancer, with particular attention to issues of vulnerability, social isolation, and patient support, in line with the mission of the Swiss GIST Group. A roundtable discussion and film screening further enriched the event, fostering dialogue between specialists, patients, and the wider public.

More than 150 participants attended this well-received event, reflecting strong engagement with these important themes. On November 15, Montemurro also chaired a public conference entitled «Parlons Santé», organized by the GIST Group from Romandie and the Clinique de Montchoisi, Lausanne.

The topics covered during this conference were as follows:

– GIST! Le b.a.-ba des tumeurs gastrointestinales stromales – M. Montemurro
– Métastases (du foie) ! Peut on guérir?, N. Halkic
– Cancer du sein! Un survol – A. Eniu
– Douleurs du dos – C. Tuleasca
– Ouff! Douleurs de l’epaule – A. Cikes

Clinique de Genolier

Hospitals

Centres

For patients

About us

Integrated care

Hospitals

Centres

For patients

About us

Integrated care

How can we help you?

Top searches

Ongoing research domains - Oncology

Dr. Matti Aapro (Clinique de Genolier)

About Matti Aapro

Scientific outputs (research, reviews, policy)

Clinical Research

Invited talks, faculty roles & moderation

Lac Leman Regenerative Medicine Symposium

ASCO Annual Meeting (panel)

ABC8

European Cancer Summit 2025

European School Of Oncology (ESO) courses (Chairman and Faculty):

Summer Edition, Basic Principles in Oncology

Dr. Alex Friedlaender (Clinique Générale-Beaulieu, Geneva)

Dr. Michael Montemurro (Clinique de Genolier)

Guidelines

Volunteering

Talks / Congress

Dr. med. Matti Aapro

Dr. med. Alexandru Eniu

PD Dr med Alex Friedlaender

Dr. med. Michael Montemurro